Clinical observation of Xuezhikang on 60 cases with HLP
Shaoping Liu
Abstract
Shaoping Liu
Abstract
[Objective] To observe the clinical curative effect of Xuezhikang on hyperlipoidemia.[Methods] The 120 cases with hyperlipoidemia were divided into two groups randomly,60 cases in each group.Treatment group was treated with Xuezhikang,and control group was treated with simvastatin.A treatment course was 8 weeks.[Results] The effective rate of treatment group was 71.7%,and the effective rate of control group was 75%.There was no significant difference between treatment group and control group(P0.05).Compared with the control group,blood lipid regulation in the treatment group of decreasing of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C) and increasing of high-density lipoprotein cholesterol(HDL-C) had no significant difference(P0.05).[Conclusion] Xuezhikang treatment of hyperlipidemia is better.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
[Objective] To observe the clinical curative effect of Xuezhikang on hyperlipoidemia.[Methods] The 120 cases with hyperlipoidemia were divided into two groups randomly,60 cases in each group.Treatment group was treated with Xuezhikang,and control group was treated with simvastatin.A treatment course was 8 weeks.[Results] The effective rate of treatment group was 71.7%,and the effective rate of control group was 75%.There was no significant difference between treatment group and control group(P0.05).Compared with the control group,blood lipid regulation in the treatment group of decreasing of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C) and increasing of high-density lipoprotein cholesterol(HDL-C) had no significant difference(P0.05).[Conclusion] Xuezhikang treatment of hyperlipidemia is better.
Key concepts: Simvastatin, Medicine, Triglyceride, Hyperlipidemia, Internal medicine, Gastroenterology, Blood lipids, Significant difference